The number of domestic pharmaceutical companies collaborating to jointly sell drugs has increased significantly. In the past, drug co-promotion contracts were mainly concluded between multinational pharmaceutical companies and domestic pharmaceutical companies.

In the pharmaceutical industry, it is interpreted as a result in which the needs of both sides are well-matched. Companies with relatively weak sales power can enjoy the effect of increasing sales and securing customers by collaborating with companies that have expertise in a specific area. Companies entering the market through joint sales can expect the effect of expanding their product lineup. Here, it is analyzed that it can be relatively adva